Wikisage, the free encyclopedia of the second generation, is digital heritage
Rufinamide: Difference between revisions
Jump to navigation
Jump to search
(Created page with "Lenox Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconcluside Rufinamide as an adjunctive therapy f...") |
mNo edit summary |
||
| Line 1: | Line 1: | ||
Lenox Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconcluside | Lenox Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconcluside | ||
Otsuka et al (2014) state efficacious and well tolerated AED | |||
<ref>[http://www.epires-journal.com/article/S0920-1211(14)00228-9/pdf | |||
Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan]</ref> | |||
<references/> | |||
Revision as of 23:06, 27 January 2016
Lenox Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconcluside Otsuka et al (2014) state efficacious and well tolerated AED [1]
- ↑ [http://www.epires-journal.com/article/S0920-1211(14)00228-9/pdf Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan]